AR115646A1 - Inhibidores de quinasas dependientes de ciclinas - Google Patents

Inhibidores de quinasas dependientes de ciclinas

Info

Publication number
AR115646A1
AR115646A1 ARP190101813A ARP190101813A AR115646A1 AR 115646 A1 AR115646 A1 AR 115646A1 AR P190101813 A ARP190101813 A AR P190101813A AR P190101813 A ARP190101813 A AR P190101813A AR 115646 A1 AR115646 A1 AR 115646A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
cycloalkyl
hydrogen
so2n
Prior art date
Application number
ARP190101813A
Other languages
English (en)
Inventor
John Tyhonas
Eric A Murphy
Stephen W Kaldor
Lee D Arnold
Toufike Kanouni
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of AR115646A1 publication Critical patent/AR115646A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Inhibidores de quinasas dependientes de ciclinas (CDK), composiciones farmacéuticas que comprenden dichos compuestos y métodos para su utilización en el tratamiento de enfermedades. Reivindicación 1: Un compuesto, o una sal farmacéuticamente aceptable o solvato del mismo, que tiene la estructura de la fórmula (1) donde, E se selecciona entre un enlace, -SO₂-, -C(O)-, -CH₂-, -CH(R⁴)-, o -C(R⁴)₂-; G se selecciona entre los grupos que tienen la estructura del grupo de fórmulas (2) donde, L es O, NH, N(C₁₋₄ alquilo opcionalmente sustituido), o -NH-CH₂-* donde el * denota el punto de unión al anillo fenilo; t es 0, 1, ó 2; u es 1, ó 2; p es 0, 1, ó 2; r es 0, 1, ó 2; R¹ se selecciona entre hidrógeno, C₁₋₄ alquilo opcionalmente sustituido, o heterociclilalquilo opcionalmente sustituido; R² se selecciona entre hidrógeno, o C₁₋₄ alquilo opcionalmente sustituido, R³ se selecciona entre hidrógeno, -CN, o C₁₋₄ alquilo opcionalmente sustituido; cada R⁴ se selecciona de manera independiente entre C₁₋₄ alquilo opcionalmente sustituido, o heterociclilalquilo opcionalmente sustituido; R⁵ puede ser C₁₋₄ alquilo opcionalmente sustituido, o heterociclilalquilo opcionalmente sustituido; cada R¹¹ es, de manera independiente hidrógeno, halógeno, C₁₋₆ alquilo opcionalmente sustituido, -OH, C₁₋₄ alcoxi opcionalmente sustituido, o dos grupos R¹¹ sobre el mismo átomo de carbono forman un oxo; R¹² es hidrógeno o C₁₋₄ alquilo opcionalmente sustituido; q es 0, 1, 2, ó 3; n es 0, 1, 2, ó 3; m es 0, 1, 2, ó 3; cada X es, de manera independiente halógeno, C₁₋₄ alquilo opcionalmente sustituido, C₁₋₄ alcoxi opcionalmente sustituido, aminoalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterociclo opcionalmente sustituido, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; Y es un grupo que se selecciona entre los restos del grupo de fórmulas (3) donde, R¹⁵ se selecciona entre hidrógeno, halógeno, -CN, alquilo opcionalmente sustituido, fluoroalquilo opcionalmente sustituido, alcoxi opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterociclo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, cicloalquil-O-opcionalmente sustituido, arilo opcionalmente sustituido, aralquilo opcionalmente sustituido, ariloxi opcionalmente sustituido, aralquiloxi opcionalmente sustituido, heteroariloxi opcionalmente sustituido, heteroaralquiloxi opcionalmente sustituido, -OR²², -N(R²²)₂, -SO₂R²¹, -N(R²²)SO₂R²¹, -SO₂N(R²²)₂, -N(R²²)SO₂N(R²²)₂, -CON(R²²)₂, -N(R²²)CO₂R²¹, -N(R²²)CON(R²²)₂, -N(R²²)COR²¹, -OC(O)N(R²²)₂, -OSO₂N(R²²)₂, o -N(R²²)SO₃R²¹; R¹⁶ se selecciona entre hidrógeno, halógeno, -CN, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, fluoroalquilo opcionalmente sustituido, alcoxi opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterociclo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, cicloalquil-O-opcionalmente sustituido, arilo opcionalmente sustituido, aralquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroaralquilo opcionalmente sustituido, ariloxi opcionalmente sustituido, aralquiloxi opcionalmente sustituido, heteroariloxi opcionalmente sustituido, heteroaralquiloxi opcionalmente sustituido, -OR²², -N(R²²)₂, -SO₂R²¹, -N(R²²)SO₂R²¹, -SO₂N(R²²)₂, -N(R²²)SO₂N(R²²)₂, -CON(R²²)₂, -N(R²²)CO₂R²¹, -N(R²²)CON(R²²)₂, -N(R²²)COR²¹, -OC(O)N(R²²)₂, -OSO₂N(R²²)₂, o -N(R²²)SO₃R²¹; R¹⁷ se selecciona entre hidrógeno, halógeno, -CN, alquilo opcionalmente sustituido, fluoroalquilo opcionalmente sustituido, alcoxi opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterociclo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, cicloalquil-O-opcionalmente sustituido, arilo opcionalmente sustituido, aralquilo opcionalmente sustituido, ariloxi opcionalmente sustituido, aralquiloxi opcionalmente sustituido, heteroariloxi opcionalmente sustituido, heteroaralquiloxi opcionalmente sustituido, -OR²², -N(R²²)₂, -SO₂R²¹, -N(R²²)SO₂R²¹, -SO₂N(R²²)₂, -N(R²²)SO₂N(R²²)₂, -CON(R²²)₂, -N(R²²)CO₂R²¹, -N(R²²)CON(R²²)₂, -N(R²²)COR²¹, -OC(O)N(R²²)₂, -OSO₂N(R²²)₂, o -N(R²²)SO₃R²¹; R¹⁸ se selecciona entre hidrógeno, halógeno, -CN, alquilo opcionalmente sustituido, fluoroalquilo opcionalmente sustituido, alcoxi opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterociclo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, cicloalquil-O-opcionalmente sustituido, arilo opcionalmente sustituido, aralquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroaralquilo opcionalmente sustituido, ariloxi opcionalmente sustituido, aralquiloxi opcionalmente sustituido, heteroariloxi opcionalmente sustituido, heteroaralquiloxi opcionalmente sustituido, -OR²², -N(R²²)₂, -SO₂R²¹, -N(R²²)SO₂R²¹, -SO₂N(R²²)₂, -N(R²²)SO₂N(R²²)₂, -CON(R²²)₂, -N(R²²)CO₂R²¹, -N(R²²)CON(R²²)₂, -N(R²²)COR²¹, -OC(O)N(R²²)₂, -OSO₂N(R²²)₂, o -N(R²²)SO₃R²¹; cada R²¹ se selecciona de manera independiente entre alquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heterociclilo, heterociclilalquilo, heteroarilo, o heteroarilalquilo; y cada R²² se selecciona de manera independiente entre hidrógeno, alquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heterociclilo, heterociclilalquilo, heteroarilo, o heteroarilalquilo.
ARP190101813A 2018-06-29 2019-06-28 Inhibidores de quinasas dependientes de ciclinas AR115646A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862691879P 2018-06-29 2018-06-29

Publications (1)

Publication Number Publication Date
AR115646A1 true AR115646A1 (es) 2021-02-10

Family

ID=68985220

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101813A AR115646A1 (es) 2018-06-29 2019-06-28 Inhibidores de quinasas dependientes de ciclinas

Country Status (14)

Country Link
US (2) US10894788B2 (es)
EP (1) EP3813819A4 (es)
JP (1) JP2021529740A (es)
KR (1) KR20210040368A (es)
CN (1) CN112638373A (es)
AR (1) AR115646A1 (es)
AU (1) AU2019291935A1 (es)
BR (1) BR112020026748A2 (es)
CA (1) CA3104131A1 (es)
IL (1) IL279791A (es)
MX (1) MX2020014245A (es)
SG (1) SG11202013175SA (es)
TW (1) TW202016094A (es)
WO (1) WO2020006497A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447493B2 (en) 2018-05-02 2022-09-20 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
CN112638373A (zh) 2018-06-29 2021-04-09 金耐特生物制药公司 细胞周期蛋白依赖性激酶抑制剂
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) * 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
AU2020315640A1 (en) * 2019-07-17 2022-03-03 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
AR119765A1 (es) 2019-08-14 2022-01-12 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
CA3166386A1 (en) * 2019-12-31 2021-07-08 Kinnate Biopharma Inc. Treatment of cancer with cdk12/13 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
EP4387965A2 (en) 2021-08-18 2024-06-26 ChemoCentryx, Inc. Aryl sulfonyl compounds as ccr6 inhibitors
CA3228553A1 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors
TW202329937A (zh) * 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024032561A1 (en) * 2022-08-08 2024-02-15 Insilico Medicine Ip Limited Inhibitors of cyclin-dependent kinase (cdk) 12 and/or cdk13 and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW249201B (es) * 1992-07-02 1995-06-11 Otsuka Pharma Co Ltd
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US20070004763A1 (en) 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
BR112014002675A2 (pt) 2011-08-04 2017-02-21 Array Biopharma Inc "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
US20140309184A1 (en) 2011-09-21 2014-10-16 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
EP3057954A2 (en) * 2013-10-18 2016-08-24 Syros Pharmaceuticals, Inc. Heteromaromatic compounds useful for the treatment of proliferative diseases
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2016073420A1 (en) * 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted azetidinyl compounds as glyt1 inhibitors
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) * 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
WO2016193939A1 (en) 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors
AU2016276963C1 (en) * 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2988330A1 (en) * 2015-06-26 2016-12-29 Dana-Farber Cancer Institute, Inc. 4,6-pyrimidinylene derivatives and uses thereof
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
GB201605126D0 (en) 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
AU2017363307B2 (en) * 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
KR20190092476A (ko) * 2016-12-19 2019-08-07 이소큐어 바이오사이언스 인코퍼레이티드 돌연변이체 이소시트레이트 탈수소효소 억제제 및 그 조성물 및 그 제조방법
WO2019035866A1 (en) * 2017-08-15 2019-02-21 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX
GB201715342D0 (en) 2017-09-22 2017-11-08 Univ Nottingham Compounds
US11447493B2 (en) 2018-05-02 2022-09-20 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
CN112638373A (zh) 2018-06-29 2021-04-09 金耐特生物制药公司 细胞周期蛋白依赖性激酶抑制剂
AU2020315640A1 (en) 2019-07-17 2022-03-03 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
CA3166386A1 (en) 2019-12-31 2021-07-08 Kinnate Biopharma Inc. Treatment of cancer with cdk12/13 inhibitors

Also Published As

Publication number Publication date
CA3104131A1 (en) 2020-01-02
US20200024266A1 (en) 2020-01-23
MX2020014245A (es) 2021-05-12
IL279791A (en) 2021-03-01
WO2020006497A1 (en) 2020-01-02
AU2019291935A1 (en) 2021-02-04
US20210130340A1 (en) 2021-05-06
SG11202013175SA (en) 2021-01-28
EP3813819A1 (en) 2021-05-05
EP3813819A4 (en) 2022-08-17
CN112638373A (zh) 2021-04-09
BR112020026748A2 (pt) 2021-03-30
JP2021529740A (ja) 2021-11-04
TW202016094A (zh) 2020-05-01
US10894788B2 (en) 2021-01-19
US11390618B2 (en) 2022-07-19
KR20210040368A (ko) 2021-04-13

Similar Documents

Publication Publication Date Title
AR115646A1 (es) Inhibidores de quinasas dependientes de ciclinas
AR103252A1 (es) Compuestos de quinazolina
AR114044A1 (es) Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central
AR107488A1 (es) Compuestos de benzopirazol y análogos de éstos
AR103297A1 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR101692A1 (es) Compuestos y métodos para inhibir histonas demetilasas
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR103574A1 (es) Compuestos tricíclicos y usos de lo mismos en medicina
AR112216A1 (es) Derivados de azaquinolina
AR091193A1 (es) HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
AR115092A1 (es) Inhibidores de magl
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR093518A1 (es) Compuestos de pirrolpirimidina como inhibidores de quinasas
AR096837A1 (es) Heterociclos tricíclicos como inhibidores de proteínas bet
AR105575A1 (es) COMPUESTOS DE QUINOLINA COMO MODULADORES DE TNFa
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR116114A1 (es) Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
AR098776A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
AR089113A1 (es) Inhibidores de quinasa
AR096332A1 (es) Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih
AR118826A1 (es) Inhibidores de cinasas raf
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2